Xeris Biopharma Holdings (XERS) Short term Debt (2023 - 2025)
Historic Short term Debt for Xeris Biopharma Holdings (XERS) over the last 3 years, with Q1 2025 value amounting to $12.0 million.
- Xeris Biopharma Holdings' Short term Debt rose 107130.26% to $12.0 million in Q1 2025 from the same period last year, while for Mar 2025 it was $12.0 million, marking a year-over-year increase of 107130.26%. This contributed to the annual value of $15.1 million for FY2024, which is 2096.92% down from last year.
- According to the latest figures from Q1 2025, Xeris Biopharma Holdings' Short term Debt is $12.0 million, which was up 107130.26% from $15.1 million recorded in Q4 2024.
- Over the past 5 years, Xeris Biopharma Holdings' Short term Debt peaked at $19.1 million during Q4 2023, and registered a low of $420000.0 during Q2 2024.
- Its 3-year average for Short term Debt is $12.4 million, with a median of $15.1 million in 2024.
- Its Short term Debt has fluctuated over the past 5 years, first tumbled by 9747.55% in 2024, then skyrocketed by 107130.26% in 2025.
- Quarter analysis of 3 years shows Xeris Biopharma Holdings' Short term Debt stood at $19.1 million in 2023, then fell by 20.97% to $15.1 million in 2024, then fell by 20.81% to $12.0 million in 2025.
- Its Short term Debt was $12.0 million in Q1 2025, compared to $15.1 million in Q4 2024 and $15.1 million in Q3 2024.